Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Other Working Capital Changes: 2020-2024

Historic Other Working Capital Changes for Oncology Institute (TOI) over the last 5 years, with FY2024 value amounting to -$2.8 million.

  • Oncology Institute's Other Working Capital Changes fell 30789.47% to -$553000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.4 million, marking a year-over-year decrease of 35554.07%. This contributed to the annual value of -$2.8 million for FY2024, which is 4688.2% up from last year.
  • Latest data reveals that Oncology Institute reported Other Working Capital Changes of -$2.8 million as of FY2024, which was up 4688.2% from -$5.3 million recorded in FY2023.
  • In the past 5 years, Oncology Institute's Other Working Capital Changes ranged from a high of $9.1 million in FY2021 and a low of -$5.3 million during FY2023
  • Its 5-year average for Other Working Capital Changes is -$391400.0, with a median of -$2.8 million in 2024.
  • As far as peak fluctuations go, Oncology Institute's Other Working Capital Changes soared by 55591.63% in 2021, and later plummeted by 14710.15% in 2022.
  • Oncology Institute's Other Working Capital Changes (Annual) stood at $1.4 million in 2020, then skyrocketed by 555.92% to $9.1 million in 2021, then plummeted by 147.1% to -$4.3 million in 2022, then decreased by 24.33% to -$5.3 million in 2023, then surged by 46.88% to -$2.8 million in 2024.
  • Its Other Working Capital Changes stands at -$2.8 million for FY2024, versus -$5.3 million for FY2023 and -$4.3 million for FY2022.